PHASE-II STUDY OF 5-FLUOROURACIL, PIRARUBICIN AND LOW-DOSE CONSECUTIVE ADMINISTRATION OF CISPLATIN FOR ADVANCED AND RECURRENT GASTRIC-CANCER

Citation
S. Kikuyama et al., PHASE-II STUDY OF 5-FLUOROURACIL, PIRARUBICIN AND LOW-DOSE CONSECUTIVE ADMINISTRATION OF CISPLATIN FOR ADVANCED AND RECURRENT GASTRIC-CANCER, Japanese Journal of Clinical Oncology, 28(5), 1998, pp. 314-317
Citations number
14
Categorie Soggetti
Oncology
ISSN journal
03682811
Volume
28
Issue
5
Year of publication
1998
Pages
314 - 317
Database
ISI
SICI code
0368-2811(1998)28:5<314:PSO5PA>2.0.ZU;2-B
Abstract
Background: The FAP regimen was modified and low-dose consecutive dail y administration of cisplatin (CDDP) and continuous infusion of 5-fluo rouracil (5-FU) and pirarubicin were employed to reduce the toxicity a nd achieve synergy. Patients with advanced and recurrent gastric cance r were treated with this regimen as early phase II trial and its effic acy and toxicity were assessed. Methods: Twenty-nine patients with adv anced or recurrent gastric cancer were treated with intravenous 5-FU, 360 mg/m(2), continuous infusion, on days 1-5 and 8-12, CDDP, 10 mg/bo dy, drip infusion, on days 1-5 and 8-12 and pirarubicin, 20 mg/body, o n days 1 and 8, which was repeated every 4 weeks. Results: One complet e (CR) and 10 partial (PR) responses were observed, Eleven patients sh owed no change (NC) and seven had progressive disease (PD), The overal l response rate (CR and PR) was 37.9%. The response rates of lymph nod e metastatic lesions and primary gastric lesions were 47 and 44%, resp ectively. The major toxicity was bone marrow suppression, which was we ll tolerated. Grade 3/4 nausea/vomiting did not occur. The median surv ival of all patients was 30 weeks, that of those who responded was 48 weeks and that of those showing NC or PD was 24 weeks. Conclusions: Th is modified FAP regimen was considered useful with a moderate response and less severe toxicity, but further investigation is necessary.